Compare · CMND vs NVO
CMND vs NVO
Side-by-side comparison of Clearmind Medicine Inc. (CMND) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMND and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 47423.1x CMND ($3.9M).
- Over the past year, CMND is down 99.0% and NVO is down 45.7% - NVO leads by 53.3 points.
- CMND has been more active in the news (12 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for CMND).
- Company
- Clearmind Medicine Inc.
- Novo Nordisk A/S
- Price
- $3.75-4.34%
- $41.01-4.51%
- Market cap
- $3.9M
- $183.15B
- 1M return
- -31.88%
- -10.44%
- 1Y return
- -99.00%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 12
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CMND
- Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on "Inside MEAI" Webinar
- SEC Form 6-K filed by Clearmind Medicine Inc.
- SEC Form 6-K filed by Clearmind Medicine Inc.
- Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
- Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
- SEC Form 6-K filed by Clearmind Medicine Inc.
- SEC Form 6-K filed by Clearmind Medicine Inc.
- SEC Form 6-K filed by Clearmind Medicine Inc.
- Clearmind Medicine Announces 1-for-10 Reverse Share Split
- SEC Form 6-K filed by Clearmind Medicine Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care